{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-24-000090","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.371899+00:00","generated_at":"2026-06-02T04:51:59.133261+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"MacroGenics posts corporate presentation with Phase 2 interim data (TAMARACK trial)","bullets":["Corporate presentation posted May 9, 2024; data cut-off April 12, 2024.","Presentation includes Phase 2 interim data from TAMARACK trial.","No specific numerical results disclosed in the 8-K excerpt; full presentation on company website.","Investors should review the complete presentation for material clinical updates."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-24-000090","json":"https://secwatch.observer/filing/0001125345-24-000090.json","markdown":"https://secwatch.observer/filing/0001125345-24-000090.md","text":"https://secwatch.observer/filing/0001125345-24-000090.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000090/0001125345-24-000090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000090/mgnx-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:51:59.133261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}